MetaVia Inc (MTVA)
MetaVia Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical candidates for cardiometabolic diseases. Its pipeline includes DA-1241, a G-protein-coupled receptor 119 agonist being studied as a standalone and potential combination therapy, and DA-1726, an oxyntomodulin analogue designed as a dual GLP-1 receptor and glucagon receptor agonist. DA-1241 is in Phase 2a testing for metabolic dysfunction-associated steatohepatitis and previously completed a Phase 1 study in type 2 diabetes, while DA-1726 is in Phase 1 development for obesity. The company also advances ANA001 for moderate COVID-19, NB-01 for painful diabetic neuropathy, NB-02 for cognitive impairment, and Gemcabene for dyslipidemia. MetaVia is headquartered in Cambridge, Massachusetts, has a license agreement with Pfizer for Gemcabene, and relies on Dong-A ST as the sole manufacturer for DA-1241 and DA-1726. Formerly known as NeuroBo Pharmaceuticals, the company adopted the MetaVia name in November 2024 and operates as a subsidiary of Dong-A ST Co., Ltd.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MTVA
|
$2.12
|
32.4% Upside
|
Undervalued
|
$19.33 1,106.2% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-0.6x
|
0.9x
|
—
|
8.676 M
|
-5.428 M
|
2.2%
|
65.5%
|
-31.9
|
—
|
115.4%
|
